Risperidone

also known as Risperdal · RISPERDAL CONSTA · RLAI · RBP-7000 · LYN-005 · RIS · Consta · RCN3028 · +23 more

Developed for: schizophrenia · schizoaffective disorder · bipolar disorder · major depressive disorder · Alzheimer disease · autism · disruptive behavior disorder · manic bipolar affective disorder
+52 more
· schizophreniform disorder · psychotic disorder · anxiety disorder · attention deficit-hyperactivity disorder · cocaine dependence · pervasive developmental disorder · bipolar I disorder · conduct disorder · dementia · depressive disorder · oppositional defiant disorder · panic disorder · post-traumatic stress disorder · vascular dementia · borderline personality disorder · developmental disability · generalized anxiety disorder · Huntington disease · mental disorder · mood disorder · schizotypal personality disorder · substance abuse · substance-related disorder · 22q11.2 deletion syndrome · adenocarcinoma · alcohol abuse · alcohol dependence · anxiety · autism spectrum disorder · bipolar depression · choreatic disease · circadian rhythm sleep disorder · cocaine abuse · delirium · delusional disorder · diabetes mellitus · drug dependence · drug-induced dyskinesia · insomnia · learning disability · methamphetamine dependence · non-small cell lung carcinoma · paranoid schizophrenia · Rett syndrome · substance dependence · Tourette syndrome · anorexia nervosa · cannabis dependence · obsessive-compulsive disorder · opiate dependence · opioid abuse · tardive dyskinesia
Investigated by: Janssen, LP · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · National Institute of Mental Health (NIMH) · Janssen Pharmaceutica N.V., Belgium · Northwell Health · AstraZeneca
+200 more
· Rovi Pharmaceuticals Laboratories · National Institute on Drug Abuse (NIDA) · Centre for Addiction and Mental Health · Indivior Inc. · Janssen-Cilag Ltd. · Janssen-Ortho Inc., Canada · Janssen Korea, Ltd., Korea · Emory University · Janssen Pharmaceutical K.K. · Janssen Research & Development, LLC · New York State Psychiatric Institute · Shanghai Mental Health Center · US Department of Veterans Affairs · University of Cologne · Washington University School of Medicine · Abbott · Central South University · Duke University · Eli Lilly and Company · Federal University of Rio Grande do Sul · German Research Network On Schizophrenia · GlaxoSmithKline · H. Lundbeck A/S · Heinrich-Heine University, Duesseldorf · Janssen Pharmaceutica · Mainz University · Martin-Luther-University Halle-Wittenberg · Ortho-McNeil Janssen Scientific Affairs, LLC · RWTH Aachen University · University Hospital Tuebingen · University of British Columbia · University of California, Los Angeles · University of Duisburg-Essen · University of Göttingen · University of Jena · University of Mannheim · University of Wuerzburg · Beth Israel Medical Center · Braeburn Pharmaceuticals · Capital Medical University · Central Institute of Mental Health, Mannheim · Changhua Christian Hospital · Children's Hospital Medical Center, Cincinnati · Columbia University · Creighton University · Dartmouth-Hitchcock Medical Center · Dr. Reddy's Laboratories Limited · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · German Federal Ministry of Education and Research · Humboldt-Universität zu Berlin · Icahn School of Medicine at Mount Sinai · Janssen Pharmaceuticals · Janssen Scientific Affairs, LLC · Janssen-Cilag International NV · Ludwig-Maximilians - University of Munich · Lyndra Inc. · Massachusetts General Hospital · National Center for Research Resources (NCRR) · Peking University · Pfizer · Research Foundation for Mental Hygiene, Inc. · Sant Pau Research Institute · Stanley Medical Research Institute · Teva Branded Pharmaceutical Products R&D, Inc. · The University of Texas Health Science Center at San Antonio · The Zucker Hillside Hospital · University of Alabama at Birmingham · University of Bonn · University of Illinois at Chicago · University of Maryland, Baltimore · University of Pittsburgh · VA Boston Healthcare System · Vanderbilt University · Weill Medical College of Cornell University · all 206 on the full record

Regulatory milestones approvals, filings & regulatory actions · 12 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	UZEDY	—	2025-10-10	fda.gov ↗
Label expansion	US (FDA)	PERSERIS KIT	—	2022-12-15	fda.gov ↗
Approved	EU (EMA)	Okedi	—	2022-02-14	europa.eu ↗
Label expansions (6)	US (FDA)	RISPERDAL	—	1997-10-17 – 2012-08-02	fda.gov ↗
Label expansions (2)	US (FDA)	RISPERDAL CONSTA	—	2007-04-12 – 2009-05-15	fda.gov ↗
Approved	US (FDA)	RISPERDAL	—	1993-12-29	fda.gov ↗

Trials 279 · started per year

today

US approved 1993

EU approved 2022

199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT03790085	Sep 2018 → Jun 2020	anxiety disorder, major depressive disorder, schizophrenia	Tianjin Medical University General Hospital	Unknown	No outcome recorded
Phase 0	NCT04587115	Jun 2017 → Jun 2019	drug dependence	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 129 trials
Phase 1	NCT07503002	Jul 2026 → Jul 2027 expected	major depressive disorder	Johns Hopkins University	Not yet recruiting	No outcome recorded
Phase 1	NCT07490353	Nov 2025 → May 2028 expected	atypical depressive disorder, major depressive disorder	Medical University of Vienna	Recruiting	No outcome recorded
Phase 1	NCT06276361	Sep 2023 → Jul 2025	schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 1	NCT05179525	Mar → Sep 2021	schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 1	NCT05491720	Aug 2020 → Mar 2022	autism spectrum disorder	The National Brain Mapping Laboratory (NBML)	Completed	No outcome recorded
Phase 1	NCT04071639	Mar 2020 → Dec 2024	Huntington disease	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 1	NCT03527186	Jul 2018 → Mar 2019	schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 1	NCT02687984	Feb → May 2016	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 1	NCT02087579	Feb → Oct 2014	bipolar disorder, depressive disorder, schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01788774	Apr 2013 → Feb 2014	schizoaffective disorder, schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 1	NCT02055287	Mar 2013 → Jun 2014	schizoaffective disorder, schizophrenia	Luye Pharma Group Ltd.	Completed	No outcome recorded
Phase 1	NCT02051387	Jan 2013 → Aug 2017	schizophrenia	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
Phase 1	NCT01708616	Nov 2012 → Feb 2013	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT01774435	Oct 2012 → Oct 2013	schizophrenia	Endo USA Inc., a Keenova Therapeutics Company	Completed	No outcome recorded
Phase 1	NCT01607762	Feb → Apr 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT02768649	Apr 2011 → Feb 2012	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 1	NCT01259973	Feb → Nov 2011	—	Hospital Clinic of Barcelona	Unknown	No outcome recorded
Phase 1	NCT02765555	Mar → Sep 2010	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 1	NCT00821600	Dec 2008 → Jun 2009	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT00698022	Nov 2008 → Feb 2009	—	Corcept Therapeutics	Completed	No outcome recorded
Phase 1	NCT00364429	Jul 2005	schizophrenia	GlaxoSmithKline	Terminated	No outcome recorded
Phase 1	NCT00269035	Jun 2005 → May 2007	schizophrenia	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01155921	Aug 2004	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT01155934	Aug 2004	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT00147394	Dec 2001 → Jun 2004	pervasive developmental disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1	NCT00986336	Feb 2001 → Nov 2002	bipolar disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT00255879	Jan 1999 → Aug 2004	drug-induced dyskinesia	University of California, San Diego	Completed	No outcome recorded
Phase 1	NCT00000339	Jun 1996 → ?	substance-related disorder	National Institute on Drug Abuse (NIDA)	Unknown	No outcome recorded
Phase 1	NCT01320410	—	—	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT04418466	Apr 2021 → Feb 2023	schizophrenia	Delpor, Inc.	Completed	No outcome recorded
Phase 1/2	NCT02650102	Jan 2013 → Dec 2016	schizophrenia	Shanxi Medical University	Unknown	No outcome recorded
Phase 1/2	NCT00133822	Apr 2004 → Sep 2006	post-traumatic stress disorder	Emory University	Completed	No outcome recorded
Phase 1/2	NCT00166595	Feb 2003 → Mar 2005	pervasive developmental disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1/2	NCT02535156	Jan 2003 → Jan 2014	schizotypal personality disorder	Sant Pau Research Institute	Completed	No outcome recorded
Phase 1/2	NCT00653406	Nov 2002 → Oct 2003	schizophrenia	Janssen Pharmaceutical K.K.	Completed	No outcome recorded
Phase 1/2	NCT01282632	Aug 2002 → Mar 2004	major depressive disorder	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 227 trials
Phase 2	NCT07152184	Oct 2026 → Feb 2032 expected	schizophrenia	University Hospital, Strasbourg, France	Not yet recruiting	No outcome recorded
Phase 2	NCT06768944	May 2026 → Dec 2027 expected	—	University of Calgary	Recruiting	No outcome recorded
Phase 2	NCT06512220	Apr 2025 → Apr 2027 expected	—	Centre for Addiction and Mental Health	Recruiting	No outcome recorded
Phase 2	NCT05710237	Jul 2023 → Apr 2026	—	Centre for Addiction and Mental Health	Completed	No outcome recorded
Phase 2	NCT04201834	Aug 2020 → Dec 2023	Huntington disease, choreatic disease	University of Rochester	Completed	No outcome recorded
Phase 2	NCT06161792	Nov 2019 → Mar 2022	breast cancer	Yung Shin Pharm. Ind. Co., Ltd.	Terminated	No outcome recorded
Phase 2	NCT02875340	Oct 2016 → Sep 2017	adenocarcinoma, non-small cell lung carcinoma	ValiSeek Limited	Completed	No outcome recorded
Phase 2	NCT02658357	Oct 2015 → Aug 2017	schizoaffective disorder, schizophrenia	Braeburn Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02462473	May 2015 → Jan 2016	schizoaffective disorder, schizophrenia	Janssen Research & Development, LLC	Terminated	No outcome recorded
Phase 2	NCT02100540	Mar 2014 → Mar 2017	premenstrual tension	Yung Shin Pharm. Ind. Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT02086786	Mar 2014 → Mar 2015	schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 2	NCT01677377	Aug 2012 → Apr 2013	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 2	NCT01411085	Dec 2011 → Aug 2014	alcohol dependence, schizophrenia	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 2	NCT00921804	Jun 2009 → May 2010	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00284206	Jan 2006 → Aug 2007	methamphetamine dependence	Seattle Institute for Biomedical and Clinical Research	Completed	No outcome recorded
Phase 2	NCT00202007	Feb → Jul 2005	schizophrenia	Otsuka Beijing Research Institute	Completed	No outcome recorded
Phase 2	NCT00073164	Jul 2003 → ?	schizophrenia	Abbott	Completed	No outcome recorded
Phase 2	NCT00206765	Jan 2003 → Jul 2005	major depressive disorder, panic disorder	Beth Israel Medical Center	Terminated	No outcome recorded
Phase 2	NCT00049946	Oct 2002 → Apr 2003	schizophrenia	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00073658	Jan 2000 → Jun 2005	dementia	University of Pittsburgh	Completed	No outcome recorded
Phase 2	NCT00000347	Jul 1997 → Aug 1998	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00004393	Jul 1997 → Sep 2000	Tourette syndrome	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00000317	Aug 1996 → Jul 1999	cocaine dependence	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00000342	Jul 1996 → Aug 1997	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00000310	Jan → Mar 1996	substance-related disorder	National Institute on Drug Abuse (NIDA)	Terminated	No outcome recorded
Phase 2	NCT00000309	Aug 1994 → Jan 2000	cocaine abuse	Butler Hospital	Terminated	No outcome recorded
Phase 2	NCT00000267	? → Dec 2001	cocaine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT00584701	Jan 2008 → May 2009	autism	University of California, San Francisco	Completed	No outcome recorded
Phase 2/3	NCT00215241	Apr 2004 → Jul 2006	post-traumatic stress disorder	Duke University	Completed	No outcome recorded
Phase 383 trials
Phase 3	NCT07565428	Apr 2026 → Dec 2027 expected	—	Minerva Neurosciences	Recruiting	No outcome recorded
Phase 3	NCT06878833	Apr 2025 → Dec 2026	schizoaffective disorder, schizophrenia	Lyndra Inc.	Withdrawn	No outcome recorded
Phase 3	NCT05779241	Apr → Nov 2023	schizoaffective disorder, schizophrenia	Lyndra Inc.	Completed	No outcome recorded
Phase 3	NCT03893825	Apr 2019 → Dec 2021	schizophrenia	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT03510325	Feb 2019 → Sep 2023	schizophrenia	Shanghai Mental Health Center	Completed	No outcome recorded
Phase 3	NCT03503318	Apr 2018 → Sep 2020	schizophrenia	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT03227562	Sep 2017 → Sep 2021	anxiety	Marion Trousselard	Terminated	No outcome recorded
Phase 3	NCT03870880	Aug 2017 → Jan 2020	schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 3	NCT03160521	Jun 2017 → Dec 2018	schizophrenia	Rovi Pharmaceuticals Laboratories	Completed	No outcome recorded
Phase 3	NCT02758067	Jun 2016	schizophrenia	H. Lundbeck A/S	Withdrawn	No outcome recorded
Phase 3	NCT02773576	Apr 2016 → Sep 2017	schizophrenia	Braeburn Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02717195	Apr 2016 → Aug 2018	schizophrenia	H. Lundbeck A/S	Completed	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT02203838	Jun 2014 → Sep 2016	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 3	NCT02109562	Apr → Nov 2014	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 3	NCT01765829	Nov 2012 → Nov 2015	psychotic disorder	Fundación Pública Andaluza Progreso y Salud	Unknown	No outcome recorded
Phase 3	NCT01624675	Sep 2012 → Oct 2014	autism	Janssen Pharmaceutical K.K.	Completed	No outcome recorded
Phase 3	NCT00347425	Dec 2006 → Feb 2008	schizophrenia	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00391222	Nov 2006 → Apr 2009	bipolar disorder	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00132314	Sep 2006 → Sep 2009	schizoaffective disorder, schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 3	NCT00828958	Feb → Sep 2006	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT02456454	Jan 2006 → Jun 2010	bipolar disorder	Nationwide Children's Hospital	Completed	No outcome recorded
Phase 3	NCT00148083	Sep 2005 → Mar 2006	schizoaffective disorder, schizophrenia	University of Illinois at Chicago	Completed	No outcome recorded
Phase 3	NCT00843687	Sep 2005 → Mar 2007	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00132678	Feb 2005 → Oct 2007	bipolar disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT01888107	Jan 2005 → Apr 2007	schizoaffective disorder, schizophrenia	Janssen-Cilag S.p.A.	Completed	No outcome recorded
Phase 3	NCT00097032	Oct 2004 → May 2005	bipolar disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00095134	Oct 2004 → Nov 2005	major depressive disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00246272	Oct 2004 → May 2006	schizophrenia	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00216476	Oct 2004 → Nov 2007	schizophrenia	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00088075	Aug 2004 → Dec 2005	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00179244	Jul 2004 → Apr 2005	major depressive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 3	NCT00167154	Jun 2004 → Apr 2007	depressive disorder	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 3	NCT00240708	Jun 2004 → Apr 2006	schizophrenia	Janssen Pharmaceutical K.K.	Completed	No outcome recorded
Phase 3	NCT00094926	May 2004 → Feb 2007	bipolar disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00283179	Mar → Dec 2004	schizoaffective disorder, schizophrenia	Taiwan Otsuka Pharm. Co., Ltd	Completed	No outcome recorded
Phase 3	NCT00216580	Feb 2004 → Dec 2006	schizophrenia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00246246	Jan 2004 → Apr 2006	bipolar disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00076115	Dec 2003 → Dec 2005	bipolar I disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00161018	Nov 2003 → Nov 2004	schizophrenia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 3	NCT00254930	Sep 2003 → Jun 2006	disruptive behavior disorder, learning disability	Janssen-Cilag Ltd.	Completed	No outcome recorded
Phase 3	NCT00057681	Feb 2003 → Dec 2008	bipolar disorder	Washington University School of Medicine	Completed	No outcome recorded
Phase 3	NCT00174577	Feb 2003 → Feb 2005	major depressive disorder	Rhode Island Hospital	Unknown	No outcome recorded
Phase 3	NCT01977300	Jan 2003 → Aug 2011	bipolar I disorder	University of British Columbia	Completed	No outcome recorded
Phase 3	NCT00044681	Oct 2002 → Mar 2004	major depressive disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00236353	May 2002 → Dec 2003	schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00034892	Mar 2002 → Mar 2005	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00287742	Mar 2002 → Mar 2003	Alzheimer disease	Janssen Pharmaceutical K.K.	Terminated	No outcome recorded
Phase 3	NCT00236470	Jan 2002 → Jul 2004	disruptive behavior disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00236444	Dec 2001 → Sep 2003	disruptive behavior disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00305422	Nov 2001 → Jan 2003	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00236587	Nov 2001 → Feb 2004	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00159770	Nov 2001 → Sep 2004	schizoaffective disorder, schizophrenia	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00495118	Oct 2001 → Mar 2005	schizoaffective disorder, schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00174590	Sep 2001 → Aug 2007	major depressive disorder	Rush University Medical Center	Terminated	No outcome recorded
Phase 3	NCT00034775	Aug 2001 → Oct 2002	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00034749	Apr 2001 → Mar 2006	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00246285	Apr 2001 → Dec 2006	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00253162	Mar 2001 → Sep 2002	manic bipolar affective disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00249236	Mar → Dec 2001	manic bipolar affective disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00034762	Dec 2000 → Jan 2003	Alzheimer disease, mental disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00257075	Dec 2000 → May 2002	manic bipolar affective disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00236457	Nov 2000 → Dec 2002	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00558298	Feb 2000 → Feb 2005	schizoaffective disorder, schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00249223	Jan → Dec 2000	schizophrenia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00210691	Dec 1999 → Feb 2004	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00253136	Nov 1999 → Dec 2000	schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00261508	Aug 1999 → Dec 2001	Rett syndrome, autism, developmental disability	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 3	NCT00399698	May 1999 → Jun 2005	adjustment disorder, attention deficit-hyperactivity disorder, bipolar disorder, conduct disorder +3	Ohio State University	Completed	No outcome recorded
Phase 3	NCT00065273	Jul 1998 → Jun 2001	developmental disability	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT00249158	Mar 1998 → Feb 2001	Alzheimer disease, vascular dementia	Janssen-Cilag Pty Ltd	Completed	No outcome recorded
Phase 3	NCT00250367	Oct 1997 → Nov 1999	manic bipolar affective disorder	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00005014	Oct 1997 → Feb 2001	autism	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 3	NCT00250354	Sep 1997 → Aug 1999	conduct disorder, disruptive behavior disorder, oppositional defiant disorder	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00249145	Apr 1995 → Dec 1996	Alzheimer disease, vascular dementia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00249132	? → Jul 1991	schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00253149	? → Apr 1999	manic bipolar affective disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00253123	? → Mar 1997	Alzheimer disease, vascular dementia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00266552	? → Oct 1998	conduct disorder, disruptive behavior disorder, oppositional defiant disorder	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00086112	? → Jun 2005	anxiety disorder	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00249119	? → Dec 1991	schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 3	NCT00297388	? → Sep 2004	schizoaffective disorder, schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00236548	? → Jan 2003	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded

Phase 495 trials
Phase 4	NCT07665073	Jun 2027 → Jun 2028 expected	bipolar I disorder	Pakistan Institute of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 4	NCT07483294	Nov 2025 → Dec 2029 expected	psychotic disorder	Northwell Health	Recruiting	No outcome recorded
Phase 4	NCT04478838	Jun 2022 → Sep 2027 expected	schizophrenia	Centre for Addiction and Mental Health	Recruiting	No outcome recorded
Phase 4	NCT04940039	Jul 2021 → Apr 2024	schizophrenia	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 4	NCT04446234	May 2021 → Dec 2022	schizophrenia	Shanghai Mental Health Center	Unknown	No outcome recorded
Phase 4	NCT03713658	Oct 2018 → Dec 2019	schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 4	NCT03323437	Sep 2017 → May 2023	schizophrenia	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 4	NCT03148509	Jun 2017 → Dec 2019	—	Peking University	Unknown	No outcome recorded
Phase 4	NCT02307396	Feb 2015 → Jun 2016	schizoaffective disorder, schizophrenia	Technical University of Munich	Completed	No outcome recorded
Phase 4	NCT02593734	Jul 2013 → Jul 2015	anxiety disorder, mood disorder, schizophrenia	University of Ghana Medical School	Completed	No outcome recorded
Phase 4	NCT01140620	Jun → Nov 2010	schizophrenia	University of Manchester	Completed	No outcome recorded
Phase 4	NCT01284959	Jun → Jul 2010	schizophrenia	Chonbuk National University Hospital	Completed	No outcome recorded
Phase 4	NCT02918097	May 2010 → Nov 2014	bipolar disorder	Federal University of Rio Grande do Sul	Completed	No outcome recorded
Phase 4	NCT01050582	Oct 2009 → Jul 2011	autism, bipolar disorder, disruptive behavior disorder, schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00937261	Jul 2009 → Jul 2010	schizophrenia	University of California, Irvine	Unknown	No outcome recorded
Phase 4	NCT01016145	Apr 2009 → Jun 2010	psychotic disorder	University of Sao Paulo	Unknown	No outcome recorded
Phase 4	NCT00794625	Nov 2008 → Nov 2012	attention deficit-hyperactivity disorder	Joseph Blader	Unknown	No outcome recorded
Phase 4	NCT00859872	Aug 2008 → Mar 2009	schizophrenia	Central South University	Completed	No outcome recorded
Phase 4	NCT00796302	Aug 2008 → Nov 2012	attention deficit-hyperactivity disorder	Michael Aman	Completed	No outcome recorded
Phase 4	NCT02021201	Jul 2008 → Jul 2013	schizophrenia	Birte Glenthoj	Terminated	No outcome recorded
Phase 4	NCT01000402	Feb 2008 → Oct 2012	attention deficit-hyperactivity disorder, bipolar disorder	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
Phase 4	NCT00622011	Jan 2008 → Mar 2009	delirium	Changhua Christian Hospital	Terminated	No outcome recorded
Phase 4	NCT00992407	Dec 2007 → Dec 2010	schizophrenia	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00576732	Dec 2007 → Sep 2009	autism	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 4	NCT01855074	Nov 2007 → Feb 2009	schizoaffective disorder, schizophrenia, schizophreniform disorder	Janssen-Cilag Ltd.	Completed	No outcome recorded
Phase 4	NCT00571688	Nov 2007 → Feb 2009	bipolar disorder	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT00535132	Oct 2007 → Jul 2008	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00498004	Aug 2007 → Sep 2008	schizophrenia	Inje University	Terminated	No outcome recorded
Phase 4	NCT00998608	Aug 2007 → Jul 2009	schizophrenia	Kaohsiung Kai-Suan Psychiatric Hospital	Terminated	No outcome recorded
Phase 4	NCT00526877	Jul 2007 → Jan 2009	schizoaffective disorder, schizophrenia	Johnson & Johnson Taiwan Ltd	Completed	No outcome recorded
Phase 4	NCT00433121	Sep 2006 → Aug 2007	dementia	Innlandet Hospital Trust	Completed	No outcome recorded
Phase 4	NCT00314327	Apr 2006 → Nov 2013	schizoaffective disorder, schizophrenia, schizophreniform disorder	Northwell Health	Terminated	No outcome recorded
Phase 4	NCT00314613	Apr → Dec 2006	schizophrenia	Duke University	Terminated	No outcome recorded
Phase 4	NCT00378092	Apr 2006 → Mar 2010	schizophrenia	Janssen Cilag N.V./S.A.	Completed	No outcome recorded
Phase 4	NCT00369239	Mar 2006 → Nov 2007	schizoaffective disorder, schizophrenia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 4	NCT00330551	Mar 2006 → Nov 2012	schizophrenia	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00333177	Mar 2006 → Jan 2013	schizophrenia	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00299702	Feb 2006 → Jan 2009	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00256997	Jan 2006 → Apr 2009	schizophrenia	Janssen-Ortho Inc., Canada	Terminated	No outcome recorded
Phase 4	NCT00854919	Jan 2006 → Dec 2007	—	Osaka City University	Completed	No outcome recorded
Phase 4	NCT01726335	Jan 2006 → Mar 2008	schizophrenia	Janssen-Cilag Ltd.	Completed	No outcome recorded
Phase 4	NCT00320671	Dec 2005 → Dec 2014	schizophrenia	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00313391	Dec 2005 → Dec 2007	schizoaffective disorder, schizophrenia	Emory University	Completed	No outcome recorded
Phase 4	NCT00216671	Nov 2005 → Dec 2009	schizophrenia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 4	NCT00130923	Sep 2005 → Jun 2009	alcohol abuse, schizophrenia	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 4	NCT00272597	Sep 2005 → Oct 2010	schizophrenia	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT00245206	Aug 2005 → Oct 2010	Alzheimer disease, schizophrenia	Veterans Medical Research Foundation	Completed	No outcome recorded
Phase 4	NCT00269919	Aug 2005 → Aug 2008	schizoaffective disorder, schizophrenia	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00216528	Jul 2005 → Apr 2007	schizophrenia	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00203723	Mar 2005 → May 2006	major depressive disorder	University of California, Los Angeles	Terminated	No outcome recorded
Phase 4	NCT00216632	Mar 2005 → Jul 2007	schizophrenia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 4	NCT00893256	Dec 2004 → Sep 2007	schizophrenia	National Institute of Mental Health and Neuro Sciences, India	Completed	No outcome recorded
Phase 4	NCT00220714	Nov 2004 → Dec 2007	schizophrenia	State University of New York - Downstate Medical Center	Unknown	No outcome recorded
Phase 4	NCT00246259	Oct 2004 → Dec 2008	schizoaffective disorder, schizophrenia, schizophreniform disorder	Janssen-Ortho Inc., Canada	Completed	No outcome recorded
Phase 4	NCT00216554	Sep 2004 → Mar 2006	bipolar disorder	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00417482	Aug 2004 → Apr 2011	Alzheimer disease, psychotic disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 4	NCT00178854	May 2004 → Mar 2006	—	Vanderbilt University Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT00215579	Apr 2004 → Apr 2006	schizoaffective disorder, schizophrenia	Duke University	Completed	No outcome recorded
Phase 4	NCT00203528	Jan 2004 → Feb 2007	bipolar depression, substance abuse	Tuscaloosa Research & Education Advancement Corporation	Completed	No outcome recorded
Phase 4	NCT00305474	Dec 2003 → Jan 2010	schizophrenia	Central South University	Unknown	No outcome recorded
Phase 4	NCT00208143	Nov 2003 → Dec 2005	schizoaffective disorder, schizophrenia, substance abuse, substance dependence	Creighton University	Completed	No outcome recorded
Phase 4	NCT00224315	Nov 2003 → Sep 2006	schizophrenia	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
Phase 4	NCT00108368	Oct 2003 → Mar 2006	schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 4	NCT00167479	Sep 2003 → Sep 2006	bipolar disorder, generalized anxiety disorder, panic disorder	University of South Florida	Completed	No outcome recorded
Phase 4	NCT00208819	Sep 2003 → Jul 2007	Alzheimer disease	Emory University	Completed	No outcome recorded
Phase 4	NCT00204347	Jul 2003 → Oct 2007	borderline personality disorder	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT00061802	Jun 2003 → Feb 2004	schizoaffective disorder, schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00485498	Apr → Dec 2003	schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00294255	Mar 2003 → Oct 2006	bipolar disorder	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 4	NCT00790075	Jan 2003 → Jun 2004	—	Stony Brook University	Completed	No outcome recorded
Phase 4	NCT00297739	Jan 2003 → Apr 2005	—	Armenteros, Jorge L., M.D., P.A.	Completed	No outcome recorded
Phase 4	NCT00848432	Dec 2002 → Dec 2004	schizophrenia	Capital Medical University	Completed	No outcome recorded
Phase 4	NCT00048802	Aug 2002 → Aug 2006	bipolar disorder	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00254241	May 2002 → Jun 2006	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00352196	Nov 2001 → May 2007	pervasive developmental disorder	Augusta University	Completed	No outcome recorded
Phase 4	NCT00159133	Nov 2001 → Jun 2006	schizophrenia	Heinrich-Heine University, Duesseldorf	Completed	No outcome recorded
Phase 4	NCT00034580	Aug 2001 → Aug 2002	bipolar disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00208182	Jul 2001 → Aug 2004	post-traumatic stress disorder	Creighton University	Completed	No outcome recorded
Phase 4	NCT00177567	Jul 2001 → Jan 2004	bipolar disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00034905	Jul 2001 → Sep 2002	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00272584	Jun 2001 → Jan 2004	schizophrenia	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT00249171	Jun 2001 → Feb 2003	schizophrenia	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 4	NCT00182013	Jun 2001 → Feb 2004	bipolar disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00181935	Mar 2001 → Jul 2004	manic bipolar affective disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00378183	Feb 2001 → May 2002	schizoaffective disorder, schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 4	NCT00014001	Dec 2000 → Dec 2004	schizophrenia	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00157378	Nov 2000 → Dec 2004	schizophrenia	Ludwig-Maximilians - University of Munich	Unknown	No outcome recorded
Phase 4	NCT00159081	Nov 2000 → Jun 2005	schizophrenia	Heinrich-Heine University, Duesseldorf	Completed	No outcome recorded
Phase 4	NCT00018668	Oct 2000 → Sep 2004	schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 4	NCT00331825	Jul 2000 → Jul 2003	extrapyramidal and movement disease, schizophrenia	Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan	Completed	No outcome recorded
Phase 4	NCT00308360	Sep 1999 → Apr 2004	schizophrenia	Nathan Kline Institute for Psychiatric Research	Completed	No outcome recorded
Phase 4	NCT00000374	Sep 1998 → May 2007	schizophrenia	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00236379	? → Aug 2003	diabetes mellitus, schizophrenia	Janssen, LP	Completed	No outcome recorded
Phase 4	NCT00626613	—	Alzheimer disease	Jinan Mental Hospital	Unknown	No outcome recorded
Phase 4	NCT00237861	? → Dec 2002	schizophrenia	Yale University	Completed	No outcome recorded

Phase not applicable34 trials
—	NCT05868720	Jul 2023 → May 2024	—	All India Institute of Medical Sciences, Bhubaneswar	Unknown	No outcome recorded
—	NCT06200584	Jan → Jun 2021	poisoning	Dr Rabia Arshad	Completed	No outcome recorded
—	NCT04478526	Apr 2020 → May 2021	generalized anxiety disorder	Dr. Nazanin Alavi	Completed	No outcome recorded
—	NCT04218981	Jan 2020 → Jun 2023	mental disorder	Central South University	Completed	No outcome recorded
—	NCT04639960	Sep 2017 → May 2021	22q11.2 deletion syndrome	University of Geneva, Switzerland	Terminated	No outcome recorded
—	NCT01931059	Jul 2013 → Jul 2016	—	Northwell Health	Completed	No outcome recorded
—	NCT04076371	Jan 2012 → Dec 2018	schizophrenia	Beijing HuiLongGuan Hospital	Completed	No outcome recorded
—	NCT02573701	Oct 2011 → Jun 2015	schizophrenia	Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico	Completed	No outcome recorded
—	NCT03019887	Apr 2011 → Jan 2017	schizophrenia	Juntendo University	Completed	No outcome recorded
—	NCT00716755	Oct 2009 → Aug 2015	delusional disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder	Centre for Addiction and Mental Health	Completed	No outcome recorded
—	NCT01878513	Sep 2009 → Jul 2018	bipolar disorder, schizoaffective disorder, schizophrenia	Northwell Health	Completed	No outcome recorded
—	NCT00931996	Jun 2009 → Nov 2011	schizophrenia	University of Illinois at Chicago	Terminated	No outcome recorded
—	NCT00825552	Jan 2009 → Jan 2010	mood disorder	Federal University of Rio Grande do Sul	Unknown	No outcome recorded
—	NCT00825045	Dec 2008 → Dec 2020	schizoaffective disorder, schizophrenia, schizophreniform disorder	Centre for Addiction and Mental Health	Unknown	No outcome recorded
—	NCT01057849	Sep 2008 → Mar 2011	schizophrenia	Peking University	Unknown	No outcome recorded
—	NCT00746252	Jun 2008 → Oct 2010	bipolar disorder	University of Maryland, Baltimore	Terminated	No outcome recorded
—	NCT00723580	May 2008 → Jul 2010	circadian rhythm sleep disorder, insomnia	Child Psychopharmacology Institute	Completed	No outcome recorded
—	NCT00493233	Nov 2006 → Dec 2008	schizophrenia	Centre for Addiction and Mental Health	Completed	No outcome recorded
—	NCT00174200	Dec 2004 → May 2006	schizophrenia	Pfizer	Completed	No outcome recorded
—	NCT00563017	Oct 2004 → Nov 2005	paranoid schizophrenia	Hospital Authority, Hong Kong	Unknown	No outcome recorded
—	NCT00633802	Apr 2004 → Apr 2009	borderline personality disorder	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
—	NCT00169988	Mar 2004 → Apr 2007	schizophrenia	Northwell Health	Completed	No outcome recorded
—	NCT00222495	Aug 2002 → Aug 2006	schizoaffective disorder, schizophrenia, schizophreniform disorder	University of Minnesota	Completed	No outcome recorded
—	NCT00203775	Jul 2002 → Apr 2004	psychotic disorder	University of Connecticut	Terminated	No outcome recorded
—	NCT00225498	Jun 2002 → Oct 2008	schizophrenia	Northwell Health	Completed	No outcome recorded
—	NCT00457106	Jun 2002 → Jun 2003	major depressive disorder, panic disorder	Beth Israel Medical Center	Completed	No outcome recorded
—	NCT01234454	Jan 2002 → Jun 2005	schizophrenia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT00015548	Mar 2001 → Oct 2004	Alzheimer disease	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
—	NCT00018291	Jan 2001 → Jan 2005	Alzheimer disease	US Department of Veterans Affairs	Completed	No outcome recorded
—	NCT00205738	Jul 2000 → Oct 2006	schizophrenia, type 2 diabetes mellitus	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00374764	Jul 2000 → Jun 2002	autism	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00012558	Sep 1998 → Sep 2005	bipolar disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
—	NCT00158028	Nov 1995 → Dec 2001	schizotypal personality disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
—	NCT00006195	—	schizophrenia	National Center for Research Resources (NCRR)	Unknown	No outcome recorded

Also used as a comparator or background therapy in 175 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT03837860 Comparator	Apr 2019 → Mar 2021	opiate dependence, opioid abuse	The University of Texas Health Science Center at San Antonio	Terminated	No outcome recorded
Phase 117 trials
Phase 1	NCT06368726 Comparator	Apr 2024 → Dec 2025 overdue	perceptual disorders, stutter disorder	Spanish Foundation for Neurometrics Development	Enrolling by invitation	No outcome recorded
Phase 1	NCT06218979 Comparator	Dec 2023 → Mar 2024	psychotic disorder	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 1	NCT05542264 Comparator	Nov 2022 → Feb 2024	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT05402111 Comparator	Jun 2022 → Sep 2023	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 1	NCT03565068 Background	Jun 2018 → Apr 2020	schizophrenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT02634463 Background	Nov 2015 → Nov 2016	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT02411526 Comparator	Feb → Sep 2015	schizoaffective disorder, schizophrenia	Zogenix, Inc.	Completed	No outcome recorded
Phase 1	NCT02091388 Comparator	Sep 2014 → Jan 2015	schizoaffective disorder, schizophrenia	Luye Pharma Group Ltd.	Completed	No outcome recorded
Phase 1	NCT02181803 Background	Aug 2014 → Apr 2015	schizophrenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT02186769 Comparator	Jul 2014 → Apr 2015	schizoaffective disorder, schizophrenia	Luye Pharma Group Ltd.	Completed	No outcome recorded
Phase 1	NCT02019329 Background	Jan → Aug 2014	schizophrenia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT01376076 Comparator	Jun 2011 → Feb 2012	schizophrenia	Forest Laboratories	Completed	No outcome recorded
Phase 1	NCT01556763 Background	Apr → Aug 2008	schizoaffective disorder, schizophrenia	FORUM Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT03730857 Comparator	Jan → Dec 2008	schizophrenia	Calo Psychiatric Center	Completed	No outcome recorded
Phase 1	NCT00466310 Comparator	Feb 2007 → Jan 2009	schizophrenia	Duke University	Completed	No outcome recorded
Phase 1	NCT00830349 Comparator	Jun → Jul 2001	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00829894 Comparator	Jun → Jul 2001	—	Teva Pharmaceuticals USA	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT02538081 Comparator	Aug 2015 → Aug 2016	schizophrenia	VA Office of Research and Development	Withdrawn	No outcome recorded
Phase 229 trials
Phase 2	NCT07575516 Background	Oct 2025 → Jan 2026	schizophrenia	Hasanuddin University	Completed	No outcome recorded
Phase 2	NCT07477301 Background	Dec 2024 → Feb 2025	schizophrenia	Hasanuddin University	Completed	No outcome recorded
Phase 2	NCT05401019 Comparator	Jun 2022 → Dec 2026	obsessive-compulsive disorder	Clinical Academic Center (2CA-Braga)	Withdrawn	No outcome recorded
Phase 2	NCT04105231 Comparator	Jun 2021 → Nov 2025 overdue	—	Lone Baandrup	Active not recruiting	No outcome recorded
Phase 2	NCT04624243 Comparator	Dec 2020 → Jun 2024	schizophrenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT04529226 Comparator	Nov 2020 → Jan 2025	intellectual disability, psychotic disorder	Andalusian Public Foundation for Health Research in Seville	Unknown	No outcome recorded
Phase 2	NCT04512066 Comparator	Sep 2020 → Jun 2022	schizoaffective disorder, schizophrenia	Hoffmann-La Roche	Completed	No outcome recorded
Phase 2	NCT04567524 Comparator	Aug → Dec 2020	schizophrenia	Lyndra Inc.	Completed	No outcome recorded
Phase 2	NCT03557931 Background	Jul 2018 → Oct 2019	schizophrenia	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 2	NCT03319953 Background	Dec 2017 → Sep 2019	schizophrenia	Neurocrine Biosciences	Completed	No outcome recorded
Phase 2	NCT03055338 Comparator	Mar 2017 → Jan 2018	schizophrenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT03887754 Comparator	Jan 2016 → Jan 2018	autism spectrum disorder	Minia University	Completed	No outcome recorded
Phase 2	NCT01623713 Comparator	Jun 2012 → Oct 2013	schizophrenia	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT01499563 Comparator	Dec 2011 → Aug 2013	schizophrenia	Intra-Cellular Therapies, Inc.	Completed	No outcome recorded
Phase 2	NCT01323205 Background	May 2011 → Nov 2012	schizophrenia	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 2	NCT01175135 Comparator	Oct 2010 → Aug 2011	schizophrenia	Pfizer	Completed	No outcome recorded
Phase 2	NCT01086748 Comparator	Mar 2010 → May 2012	schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT01083381 Comparator	Feb → Oct 2010	schizophrenia	Farzan Institute	Unknown	No outcome recorded
Phase 2	NCT01052103 Background	Jan 2010 → Jun 2012	schizophrenia	Denovo Biopharma LLC	Completed	No outcome recorded
Phase 2	NCT00845026 Comparator	Mar 2009 → May 2010	schizophrenia	Denovo Biopharma LLC	Completed	No outcome recorded
Phase 2	NCT00768612 Comparator	Nov 2008 → Jul 2009	schizophrenia	Wyeth is now a wholly owned subsidiary of Pfizer	Withdrawn	No outcome recorded
Phase 2	NCT01171937 Comparator	Sep 2008 → Sep 2016	autism	University of California, Los Angeles	Completed	No outcome recorded
Phase 2	NCT00567710 Comparator	Jul 2008 → Jul 2009	schizophrenia	BioLineRx, Ltd.	Completed	No outcome recorded
Phase 2	NCT00694707 Comparator	Jun 2008 → Aug 2009	schizophrenia	Forest Laboratories	Completed	No outcome recorded
Phase 2	NCT00722176 Comparator	Jun 2008 → Jul 2009	schizophrenia	BioLineRx, Ltd.	Completed	No outcome recorded
Phase 2	NCT00563706 Comparator	Dec 2007 → Jun 2008	schizophrenia	Pfizer	Completed	No outcome recorded
Phase 2	NCT00509067 Background	Nov 2007 → Mar 2011	schizophrenia	Georgetown University	Completed	No outcome recorded
Phase 2	NCT00099983 Comparator	Oct 2006 → Feb 2010	post-traumatic stress disorder	US Department of Veterans Affairs	Completed	No outcome recorded
Phase 2	NCT00385801 Comparator	Sep 2005 → Sep 2010	cocaine dependence	Massachusetts General Hospital	Completed	No outcome recorded

Phase 2/36 trials
Phase 2/3	NCT01626872 Comparator	Sep 2012 → Oct 2016	schizophrenia	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 2/3	NCT01625897 Comparator	May 2012 → Mar 2015	schizophrenia	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 2/3	NCT01625000 Comparator	May 2012 → Aug 2015	schizophrenia	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 2/3	NCT01363349 Comparator	May 2011 → Mar 2013	schizophrenia	BioLineRx, Ltd.	Terminated	No outcome recorded
Phase 2/3	NCT01129674 Comparator	Jun 2010 → Oct 2012	schizophrenia	Eli Lilly and Company	Terminated	No outcome recorded
Phase 2/3	NCT00910780 Comparator	Nov 2009	diabetes mellitus	Washington University School of Medicine	Withdrawn	No outcome recorded

Phase 327 trials
Phase 3	NCT06482554 Comparator	Jun 2024 → Dec 2026 expected	schizophrenia	Louisiana State University Health Sciences Center Shreveport	Recruiting	No outcome recorded
Phase 3	NCT03230864 Background	Jul 2017 → Dec 2018	schizophrenia	H. Lundbeck A/S	Terminated	No outcome recorded
Phase 3	NCT02431702 Comparator	Jul 2015 → Nov 2019	schizophrenia	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 3	NCT02469155 Comparator	Jun 2015 → Aug 2016	schizophrenia	Intra-Cellular Therapies, Inc.	Completed	No outcome recorded
Phase 3	NCT02002832 Comparator	Dec 2013 → Apr 2015	schizophrenia	Marubeni Pharmaceuticals (Suzhou) Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02453893 Comparator	Nov 2013 → Jun 2015	schizophrenia	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT01516424 Comparator	Feb 2012 → Feb 2013	schizophrenia	Marubeni Pharmaceuticals (Suzhou) Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01295372 Comparator	Apr 2011 → Oct 2012	schizophrenia	H. Lundbeck A/S	Completed	No outcome recorded
Phase 3	NCT01081769 Comparator	Feb 2010 → Feb 2013	schizophrenia	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00857818 Comparator	Apr 2009 → Mar 2010	bipolar I disorder, metabolic syndrome X, schizoaffective disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Terminated	No outcome recorded
Phase 3	NCT00660595 Comparator	Sep → Dec 2008	schizophrenia	AstraZeneca	Terminated	No outcome recorded
Phase 3	NCT00711269 Comparator	Jun 2008 → Apr 2010	schizophrenia	Sumitomo Pharma Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT00641745 Comparator	Mar 2008 → Jul 2010	schizoaffective disorder, schizophrenia	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT00640562 Comparator	Feb 2008 → Feb 2010	depressive disorder, schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00600756 Comparator	Jan 2008 → Oct 2009	schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00604279 Comparator	Jan 2008 → Jan 2009	schizophrenia	Xian-Janssen Pharmaceutical Ltd.	Completed	No outcome recorded
Phase 3	NCT00589914 Comparator	Mar 2007 → Jun 2009	schizophrenia	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00366704 Comparator	Nov 2006 → Mar 2008	schizophrenia	Wyeth is now a wholly owned subsidiary of Pfizer	Terminated	No outcome recorded
Phase 3	NCT00435370 Background	Nov 2006 → Feb 2011	schizophrenia	Baylor College of Medicine	Completed	No outcome recorded
Phase 3	NCT00221403 Comparator	Sep 2004 → May 2011	bipolar I disorder	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 3	NCT00237913 Comparator	Jul 2004 → Aug 2005	schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 3	NCT00645372 Comparator	Jul 2004 → May 2005	schizophrenia	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00277654 Comparator	Feb 2004 → Mar 2009	anxiety disorder, bipolar disorder	Lindner Center of HOPE	Completed	No outcome recorded
Phase 3	NCT00177164 Comparator	Nov 2003 → Mar 2008	bipolar I disorder	University of Pittsburgh	Completed	No outcome recorded
Phase 3	NCT00645515 Comparator	Jun → Dec 2003	schizophrenia	Viatris Inc.	Terminated	No outcome recorded
Phase 3	NCT00176202 Comparator	Apr 2003 → Jan 2008	bipolar disorder	University of Illinois at Chicago	Completed	No outcome recorded
Phase 3	NCT00856583 Comparator	Jul 2002 → Feb 2008	schizophrenia	H. Lundbeck A/S	Completed	No outcome recorded

Phase 468 trials
Phase 4	NCT06969755 Comparator	Sep 2025 → Jul 2030 expected	schizophrenia	Northwell Health	Recruiting	No outcome recorded
Phase 4	NCT07047651 Background	Jun 2025 → Dec 2027 expected	treatment-refractory schizophrenia	Dr. Stavroula Rakitzi	Active not recruiting	No outcome recorded
Phase 4	NCT06236451 Comparator	Apr 2024 → Nov 2025	schizophrenia	All India Institute of Medical Sciences, Bhubaneswar	Completed	No outcome recorded
Phase 4	NCT05741502 Comparator	Aug 2023 → Jan 2026	schizophrenia	Ohio State University	Terminated	No outcome recorded
Phase 4	NCT05890768 Comparator	May 2023 → Feb 2024	psychotic disorder	University of New Mexico	Withdrawn	No outcome recorded
Phase 4	NCT04580134 Comparator	Mar 2022 → Apr 2027 expected	bipolar I disorder, schizoaffective disorder, schizophrenia	University of Texas Southwestern Medical Center	Recruiting	No outcome recorded
Phase 4	NCT04903353 Comparator	Feb 2022 → Dec 2025	autism spectrum disorder	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT03978832 Background	Jun 2019 → May 2020	schizophrenia	Indivior Inc.	Completed	No outcome recorded
Phase 4	NCT03568500 Background	May 2018 → May 2019	schizoaffective disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 4	NCT03075657 Comparator	May 2017 → Jun 2018	schizophrenia	All India Institute of Medical Sciences, Bhubaneswar	Completed	No outcome recorded
Phase 4	NCT02063945 Comparator	Feb 2017 → Feb 2018	attention deficit-hyperactivity disorder, conduct disorder, oppositional defiant disorder	Sheba Medical Center	Terminated	No outcome recorded
Phase 4	NCT02562287 Comparator	Oct 2015 → Jun 2019	bipolar disorder	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
Phase 4	NCT03883204 Comparator	Jan 2015 → Dec 2020	schizophrenia	Fundación Marques de Valdecilla	Unknown	No outcome recorded
Phase 4	NCT02282085 Comparator	Dec 2014 → Dec 2017	schizophrenia	Matt Byerly	Unknown	No outcome recorded
Phase 4	NCT02237417 Comparator	Sep 2014 → Nov 2018	schizophrenia	University of Utah	Completed	No outcome recorded
Phase 4	NCT03090503 Comparator	Jun 2014 → Jun 2019	schizophrenia	Fundación Marques de Valdecilla	Unknown	No outcome recorded
Phase 4	NCT02532491 Comparator	May 2014 → May 2018	schizophrenia	Fundación Marques de Valdecilla	Unknown	No outcome recorded
Phase 4	NCT02040883 Background	Feb → Dec 2014	schizophrenia	Qingyun Yin	Unknown	No outcome recorded
Phase 4	NCT01844700 Comparator	Jul 2013 → Apr 2014	obesity due to melanocortin 4 receptor deficiency	Northwell Health	Terminated	No outcome recorded
Phase 4	NCT01639872 Comparator	May 2013 → Mar 2017	cannabis dependence, schizophrenia, substance abuse	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 4	NCT01913327 Comparator	Apr 2013 → Jan 2017	schizoaffective disorder, schizophrenia, schizophreniform disorder	University of California, San Francisco	Terminated	No outcome recorded
Phase 4	NCT01822730 Comparator	Feb 2013 → Jan 2014	methamphetamine dependence	Wei Hao	Completed	No outcome recorded
Phase 4	NCT01742390 Comparator	Feb → Dec 2013	hyperprolactinemia, sexual disorder	Si Tianmei	Unknown	No outcome recorded
Phase 4	NCT01670071 Comparator	Jan 2013 → Jun 2015	schizophrenia	Johnson & Johnson Taiwan Ltd	Terminated	No outcome recorded
Phase 4	NCT01592201 Background	Jul 2012 → Jun 2013	schizophrenia	Janssen Korea, Ltd., Korea	Terminated	No outcome recorded
Phase 4	NCT01813643 Comparator	Jul 2012 → Dec 2013	methamphetamine dependence	Wei Hao	Terminated	No outcome recorded
Phase 4	NCT01451736 Comparator	Oct 2011 → Dec 2021	schizophrenia	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT01495156 Background	Sep 2011 → Sep 2014	bipolar I disorder	Northwell Health	Withdrawn	No outcome recorded
Phase 4	NCT01333072 Comparator	Jul 2011 → Aug 2015	autism	Medical University of South Carolina	Completed	No outcome recorded
Phase 4	NCT02118688 Comparator	Mar 2011 → Mar 2016	delirium	Rochester General Hospital	Withdrawn	No outcome recorded
Phase 4	NCT01193166 Comparator	Aug 2010 → Sep 2012	schizophrenia	Ortho-McNeil Janssen Scientific Affairs, LLC	Withdrawn	No outcome recorded
Phase 4	NCT01157351 Comparator	May 2010 → Dec 2013	schizophrenia	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 4	NCT00934635 Comparator	Sep → Dec 2009	schizophrenia	Janssen-Cilag GmbH	Terminated	No outcome recorded
Phase 4	NCT01305707 Comparator	Jul 2009 → Jul 2014	major depressive disorder	Hospital Universitari de Bellvitge	Terminated	No outcome recorded
Phase 4	NCT00946985 Comparator	Jun 2009 → Mar 2010	schizophrenia	Ortho-McNeil Janssen Scientific Affairs, LLC	Terminated	No outcome recorded
Phase 4	NCT00806234 Comparator	Jan 2009 → Mar 2014	psychotic disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00817648 Comparator	Dec 2008 → May 2010	schizophrenia	Shanghai Mental Health Center	Completed	No outcome recorded
Phase 4	NCT00827840 Comparator	Nov 2008 → Feb 2011	schizophrenia	Chonnam National University Hospital	Completed	No outcome recorded
Phase 4	NCT00480844 Comparator	Oct 2008 → Oct 2011	schizophrenia	Sheba Medical Center	Unknown	No outcome recorded
Phase 4	NCT00761670 Comparator	Sep 2008 → Jan 2010	schizophrenia	Sanofi	Completed	No outcome recorded
Phase 4	NCT00594269 Comparator	Aug 2008 → Dec 2010	dementia	Innlandet Hospital Trust	Completed	No outcome recorded
Phase 4	NCT01119638 Comparator	Apr 2008 → Apr 2010	Alzheimer disease, psychotic disorder	Abarbanel Mental Health Center	Completed	No outcome recorded
Phase 4	NCT00539071 Comparator	Mar 2008 → May 2012	schizoaffective disorder, schizophrenia	Northwestern University	Completed	No outcome recorded
Phase 4	NCT00508157 Comparator	Nov 2007 → Mar 2009	metabolic syndrome X, schizophrenia	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 4	NCT00418873 Comparator	Mar 2007 → Dec 2009	schizophrenia	Astellas Pharma Inc	Terminated	No outcome recorded
Phase 4	NCT00423878 Comparator	Jan 2007 → Oct 2009	schizoaffective disorder, schizophrenia	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 4	NCT00325689 Comparator	Jul 2006 → Oct 2007	schizoaffective disorder, schizophrenia	Otsuka Pharmaceutical Development & Commercialization, Inc.	Completed	No outcome recorded
Phase 4	NCT00338949 Comparator	Jun 2006 → Dec 2009	metabolic syndrome X, schizophrenia	Veterans Medical Research Foundation	Completed	No outcome recorded
Phase 4	NCT00337662 Comparator	May 2006 → Dec 2007	schizoaffective disorder, schizophrenia, schizophreniform disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00330863 Comparator	May 2006 → Jan 2011	schizoaffective disorder, schizophrenia	Northwell Health	Completed	No outcome recorded
Phase 4	NCT00205699 Comparator	Apr 2006 → Mar 2011	attention deficit-hyperactivity disorder, bipolar disorder, oppositional defiant disorder, pervasive developmental disorder	Washington University School of Medicine	Completed	No outcome recorded
Phase 4	NCT00712270 Comparator	Apr 2005 → Dec 2008	schizophrenia	Kettering Health Network	Terminated	No outcome recorded
Phase 4	NCT00654576 Comparator	Feb 2005 → Dec 2007	schizophrenia	Central South University	Completed	No outcome recorded
Phase 4	NCT00304616 Background	Oct 2004 → Jun 2006	schizophrenia	Korea Otsuka Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT00140426 Comparator	Aug 2004 → Dec 2009	anorexia nervosa	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT00287820 Comparator	Feb 2004 → Sep 2007	diabetes mellitus, hyperglycemia, metabolic syndrome X, schizophrenia	Nathan Kline Institute for Psychiatric Research	Completed	No outcome recorded
Phase 4	NCT00190749 Comparator	Oct 2003 → Jun 2008	schizoaffective disorder, schizophrenia	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00206102 Comparator	Sep 2003 → Oct 2008	schizoaffective disorder, schizophrenia	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00932529 Comparator	Feb 2003 → Jan 2010	psychotic disorder	University of Bergen	Completed	No outcome recorded
Phase 4	NCT00289861 Comparator	Feb 2003 → Mar 2007	schizophrenia	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT00053703 Comparator	Feb 2002 → May 2007	schizophrenia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 4	NCT00056498 Comparator	Dec 2001 → Dec 2007	schizophrenia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT00044655 Comparator	Jul 2001 → Mar 2009	schizophrenia	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT00768820 Background	May 2001 → Aug 2027 expected	Williams syndrome, fragile X syndrome, velocardiofacial syndrome	The Chaim Sheba Medical Center	Recruiting	No outcome recorded
Phase 4	NCT00621998 Comparator	Jul 2000 → Dec 2003	tardive dyskinesia	Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan	Completed	No outcome recorded
Phase 4	NCT00183625 Comparator	Jun 2000 → Jun 2005	schizophrenia	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00203788 Background	May 1999 → Dec 2006	schizophrenia	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT00253110 Comparator	May 1996 → Sep 1998	schizoaffective disorder, schizophrenia	Janssen, LP	Completed	No outcome recorded

Phase not applicable26 trials
—	NCT07523256 Background	Nov 2025 → Jan 2026	schizophrenia	Rinvil Renaldi	Completed	No outcome recorded
—	NCT07524868 Background	Nov 2025 → Jan 2026	perceptual disorders, schizophrenia	Hasanuddin University	Completed	No outcome recorded
—	NCT07609953 Background	Nov 2025 → Jan 2026	schizophrenia	Hasanuddin University	Completed	No outcome recorded
—	NCT07541157 Background	Sep 2025 → Jan 2026	schizophrenia	Hasanuddin University	Completed	No outcome recorded
—	NCT07060872 Background	Jul → Sep 2025 overdue	autism spectrum disorder	Shahid Sadoughi University of Medical Sciences and Health Services	Not yet recruiting	No outcome recorded
—	NCT07671040 Background	Mar → Jun 2025	schizophrenia	Hasanuddin University	Completed	No outcome recorded
—	NCT06581302 Comparator	Sep 2024 → Dec 2025 overdue	psychotic disorder	Shanghai Jiao Tong University School of Medicine	Recruiting	No outcome recorded
—	NCT07116850 Background	Jan → Dec 2024	schizophrenia	The First Hospital of Hebei Medical University	Completed	No outcome recorded
—	NCT02926976 Comparator	Nov 2016 → Sep 2019	schizophrenia	Shanghai Mental Health Center	Unknown	No outcome recorded
—	NCT02661347 Comparator	Feb → Dec 2016	schizoaffective disorder, schizophrenia, schizophreniform disorder	Northwell Health	Withdrawn	No outcome recorded
—	NCT01786239 Background	May 2013 → Sep 2015	bipolar disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder	Delbert Robinson	Completed	No outcome recorded
—	NCT01896349 Background	Apr 2013 → Aug 2014	—	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
—	NCT01724372 Comparator	Oct 2012 → May 2014	psychotic disorder	St. Luke's-Roosevelt Hospital Center	Withdrawn	No outcome recorded
—	NCT02137616 Comparator	Jun 2012 → Dec 2014	psychotic disorder	Central South University	Unknown	No outcome recorded
—	NCT02192723 Comparator	Jun 2012 → Jun 2014	schizophrenia	Beijing HuiLongGuan Hospital	Completed	No outcome recorded
—	NCT01510015 Comparator	Jan 2012 → Oct 2013	cannabis dependence	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
—	NCT01770600 Comparator	Apr 2010 → Sep 2013	impulse control disorder, major depressive disorder	University of Alabama at Birmingham	Withdrawn	No outcome recorded
—	NCT00629252 Comparator	Feb 2008 → Aug 2012	schizophrenia	University of Zurich	Terminated	No outcome recorded
—	NCT00389493 Comparator	Oct 2006 → Jun 2012	obsessive-compulsive disorder	New York State Psychiatric Institute	Completed	No outcome recorded
—	NCT00534183 Comparator	Jun → Dec 2006	diabetes mellitus, metabolic syndrome X, obesity disorder	Central Institute of Psychiatry, Ranchi, India	Completed	No outcome recorded
—	NCT00573287 Comparator	Jun 2006 → Dec 2010	schizophrenia, substance-related disorder	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
—	NCT00080145 Comparator	Feb 2004 → Sep 2007	pervasive developmental disorder	Yale University	Completed	No outcome recorded
—	NCT00227123 Comparator	Oct 2002 → Nov 2006	bipolar disorder, cocaine dependence, methamphetamine dependence	University of Texas Southwestern Medical Center	Completed	No outcome recorded
—	NCT00515723 Comparator	Sep 2001 → Dec 2008	hyperglycemia, schizoaffective disorder, schizophrenia, type 2 diabetes mellitus	Washington University School of Medicine	Completed	No outcome recorded
—	NCT00179062 Comparator	Feb 2000 → Jun 2007	bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia	Vanderbilt University	Completed	No outcome recorded
—	NCT00206960 Comparator	Jan 1998 → Sep 2010	schizophrenia	Birte Glenthoj	Completed	No outcome recorded

Press releases naming this drug 39 releases

Date	Issuer	Release
2025-10-10	Teva Branded Pharmaceutical Products R&D, Inc.	FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder tevapharm.com ↗
2025-10-10	Teva Branded Pharmaceutical Products R&D, Inc.	FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder tevapharm.com ↗
2025-05-31	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date tevapharm.com ↗
2025-05-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date tevapharm.com ↗
2025-02-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder tevapharm.com ↗
2025-02-25	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder tevapharm.com ↗
2024-11-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) tevapharm.com ↗
2024-09-21	Teva Branded Pharmaceutical Products R&D, Inc.	New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) tevapharm.com ↗
2024-06-01	Teva Branded Pharmaceutical Products R&D, Inc.	New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) tevapharm.com ↗
2024-04-06	Teva Branded Pharmaceutical Products R&D, Inc.	New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 tevapharm.com ↗
2023-11-01	Teva Branded Pharmaceutical Products R&D, Inc.	UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry tevapharm.com ↗
2023-09-06	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023 tevapharm.com ↗
2023-05-20	Teva Branded Pharmaceutical Products R&D, Inc.	Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting tevapharm.com ↗
2023-04-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults tevapharm.com ↗
2022-04-19	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM tevapharm.com ↗
2021-10-30	Teva Branded Pharmaceutical Products R&D, Inc.	New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia tevapharm.com ↗
2021-08-31	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia tevapharm.com ↗
2021-01-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia tevapharm.com ↗
2018-04-18	Otsuka Pharmaceutical Development & Commercialization, Inc.	REXULTI Tablets, a New Antipsychotic Drug, Launched in Japan® otsuka.co.jp ↗
2018-01-19	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia ® otsuka.co.jp ↗
2016-11-18	Otsuka Pharmaceutical Development & Commercialization, Inc.	New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan otsuka.co.jp ↗
2016-09-28	Otsuka Pharmaceutical Development & Commercialization, Inc.	Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder otsuka.co.jp ↗
2015-12-07	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism otsuka.co.jp ↗
2015-05-07	Takeda	Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate their Agreement for the Joint Development and Exclusive Commercialization of Latuda ® (lurasidone) - an Atypical Antipsychotic Agent, in Europe takeda.com ↗
2014-03-31	Takeda	Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda ® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia takeda.com ↗
2014-02-25	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka's Antipsychotic Aripiprazole Awarded the 60th Okochi Memorial Prize otsuka.co.jp ↗
2014-01-27	Takeda	Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia takeda.com ↗
2012-09-03	Otsuka Pharmaceutical Development & Commercialization, Inc.	ABILIFY® ,The First Antipsychotic Agent in Japan Applying for Adjunctive Treatment in Major Depressive Disorder otsuka.co.jp ↗
2012-04-17	Otsuka Pharmaceutical Development & Commercialization, Inc.	New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Adherence otsuka.co.jp ↗
2012-01-18	Otsuka Pharmaceutical Development & Commercialization, Inc.	Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets" otsuka.co.jp ↗
2009-03-25	Otsuka Pharmaceutical Development & Commercialization, Inc.	Antipsychotic agent ABILIFY Oral Solution 0.1% to be Launched on April 10, 2009 in Japan® otsuka.co.jp ↗
2009-01-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Generic Risperdal ® Oral Solution tevapharm.com ↗
2008-09-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Appellate Court Reverses Generic Risperdal® Exclusivity Decision tevapharm.com ↗
2008-06-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives First U.S. Approval For Generic Risperdal® Tablets; Commences Commercial Launch tevapharm.com ↗
2008-04-11	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives Court Ruling Awarding Exclusivity For Generic Risperdal® tevapharm.com ↗
2008-03-05	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update On Generic Risperdal® tevapharm.com ↗
2006-10-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval for Generic Risperdal® Oral Solution tevapharm.com ↗
2006-06-06	Otsuka Pharmaceutical Development & Commercialization, Inc.	Drug to treat schizophrenia with a new mechanism of action Antipsychotic agent "Abilify" Available in Japan from June 8 ® otsuka.co.jp ↗
2006-01-25	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka's Antipsychotic Abilify Is Approved in Japan, January 23, 2006® otsuka.co.jp ↗

Evidence & citations 35 cited values

Every value below carries the sentence it was read from. 460 sources stand behind the page.

Field	Value	Cited text
Known as	risperidone	“Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗ 437 “Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗ “The purpose of this study is to examine the safety and effectiveness of the long acting injectable form of the atypical antipsychotic Risperidone (Risperdal CONSTA), along with...” NCT00094926 ↗ “In case of early signs of a relapse prodrome based early intervention with an antipsychotic drug (Haloperidol, Risperidone and other) vs. benzodiazepine (Lorazepam) was applied...” NCT00159133 ↗ “If the patient is within the primary medication arm and reports a 20-50% improvement in GAD symptoms compared to baseline after six weeks on the new medication, the medication...” NCT04478526 ↗ “Subjects (N = 44) who failed to respond to SSRIs were randomly assigned to 1 of 3 atypical antipsychotics -- olanzapine, quetiapine, or risperidone -- and were consecutively...” PMID 19422759 ↗ May 2009 “Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per...” NCT01081769 ↗ “The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test...” NCT00179244 ↗ “For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone,...” NCT02181803 ↗ “RYKINDO® (Rykindo) is a novel, long-acting injectable risperidone formulation administered biweekly (Q2W) through intramuscular gluteal injection for the treatment of...” PMID 38244179 ↗ Jan 2024 “This study was developed in order to assess the effects of risperidone (Risperdal) as compared with placebo on cognitive-motor performance (attention, memory, and hand...” NCT00399698 ↗ “The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit...” NCT00148083 ↗ “Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\])” NCT01556763 ↗ “Risperidone, long-acting formulation for intramuscular injections (25 to 50 mg (maximum)), given every 14 days through 6 months, starting at baseline or Month 3.” NCT00216671 ↗ “United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)” NCT01052103 ↗ “Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.” NCT03319953 ↗ “Most recently, one of the atypical medications - risperidone - became available as a long-acting injection that can be given once every 2 weeks.” NCT00220714 ↗ “Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics” NCT05741502 ↗ “A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.” NCT02687984 ↗ “Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.” NCT00338949 ↗ “VAL401 is a formulation of Risperidone (active pharmaceutical ingredient) in a liquid lipid filled capsule.” NCT02875340 ↗ “Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg” NCT01016145 ↗ “Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group” NCT04218981 ↗ “RISPERDAL CONSTA (risperidone long-acting injection) may provide substantial improvement” NCT00132678 ↗ “Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day” NCT01495156 ↗ “Oral risperidone 0.25 mg tablets daily for the first two days of the screening period.” NCT02109562 ↗ “Risperidone is the first line antipsychotic followed by others per clinician choice.” NCT00931996 ↗ “Administer pill of risperidone 1 mg once a day by mouth for 5 days.” NCT01770600 ↗ “RISPERDAL CONSTA (Risperidone Long-Acting Intramuscular Injection)” NCT00589914 ↗ “Risperidone (according to response, and tolerance)0.5-6mg” NCT01000402 ↗ “1 injection of 25 mg of Risperidone for each subject” NCT01320410 ↗ “EN3342 (risperidone) subcutaneous implant” NCT01774435 ↗ “aripirprazole, lurasidone, risperidone” NCT03565068 ↗ “- Risperidone 0'5-9 mg/d. N05AX08” NCT01305707 ↗ “risperidone (Risperdal®)” NCT02237417 ↗ NCT00099983 ↗ NCT01844700 ↗ NCT00088075 ↗ NCT00389493 ↗ NCT00495118 ↗ NCT00246246 ↗ NCT00161018 ↗ NCT00433121 ↗ NCT07565428 ↗ NCT01708616 ↗ NCT00600756 ↗ NCT00246285 ↗ NCT01333072 ↗ NCT00498004 ↗ NCT02087579 ↗ NCT00206960 ↗ NCT00573287 ↗ NCT00250367 ↗ NCT00378092 ↗ NCT00921804 ↗ NCT02538081 ↗ NCT00297739 ↗ NCT03713658 ↗ NCT00378183 ↗ NCT00828958 ↗ NCT00246272 ↗ NCT00073658 ↗ NCT00297388 ↗ NCT01913327 ↗ NCT02918097 ↗ NCT02411526 ↗ NCT00859872 ↗ NCT00250354 ↗ NCT00061802 ↗ NCT00304616 ↗ NCT00843687 ↗ NCT00283179 ↗ NCT00073164 ↗ NCT00558298 ↗ NCT05402111 ↗ NCT07483294 ↗ NCT00236587 ↗ NCT00325689 ↗ NCT00057681 ↗ NCT00320671 ↗ NCT00182013 ↗ NCT00746252 ↗ NCT00986336 ↗ NCT01451736 ↗ NCT00712270 ↗ NCT00204347 ↗ NCT00097032 ↗ NCT06236451 ↗ NCT03527186 ↗ NCT00216476 ↗ NCT00723580 ↗ NCT01363349 ↗ NCT00215579 ↗ NCT04940039 ↗ NCT00206765 ↗ NCT00515723 ↗ NCT03887754 ↗ NCT06512220 ↗ NCT07609953 ↗ NCT00210691 ↗ NCT00998608 ↗ NCT00147394 ↗ NCT00246259 ↗ NCT00000374 ↗ NCT01878513 ↗ NCT00417482 ↗ NCT00080145 ↗ NCT01726335 ↗ NCT00633802 ↗ NCT04201834 ↗ NCT02462473 ↗ NCT00216528 ↗ NCT00222495 ↗ NCT00034905 ↗ NCT00830349 ↗ NCT00418873 ↗ NCT00369239 ↗ NCT00768820 ↗ NCT04076371 ↗ NCT07047651 ↗ NCT00181935 ↗ NCT01193166 ↗ NCT00269919 ↗ NCT00294255 ↗ NCT02532491 ↗ NCT00174200 ↗ NCT01295372 ↗ NCT06969755 ↗ NCT00018668 ↗ NCT00158028 ↗ NCT04418466 ↗ NCT00937261 ↗ NCT00466310 ↗ NCT01592201 ↗ NCT02773576 ↗ NCT00203723 ↗ NCT01625897 ↗ NCT00305422 ↗ NCT00287742 ↗ NCT01516424 ↗ NCT00305474 ↗ NCT00539071 ↗ NCT00287820 ↗ NCT00825552 ↗ NCT00190749 ↗ NCT05491720 ↗ NCT00333177 ↗ NCT00018291 ↗ NCT01625000 ↗ NCT00255879 ↗ NCT01129674 ↗ NCT06276361 ↗ NCT03870880 ↗ NCT00167479 ↗ NCT01411085 ↗ NCT00253123 ↗ NCT00216554 ↗ NCT00237861 ↗ NCT00821600 ↗ NCT00584701 ↗ NCT01624675 ↗ NCT04903353 ↗ NCT07490353 ↗ NCT01813643 ↗ NCT02562287 ↗ NCT01822730 ↗ NCT00216580 ↗ NCT00253136 ↗ NCT00216632 ↗ NCT00347425 ↗ NCT02768649 ↗ NCT01119638 ↗ NCT01855074 ↗ NCT00249236 ↗ NCT00331825 ↗ NCT00249223 ↗ NCT00048802 ↗ NCT00208182 ↗ NCT05868720 ↗ NCT00240708 ↗ NCT00253149 ↗ NCT00034892 ↗ NCT05710237 ↗ NCT00237913 ↗ NCT00225498 ↗ NCT00253162 ↗ NCT00253110 ↗ NCT00215241 ↗ NCT00000347 ↗ NCT00249171 ↗ NCT00202007 ↗ NCT00249158 ↗ NCT03557931 ↗ NCT00159081 ↗ NCT01742390 ↗ NCT06218979 ↗ NCT02040883 ↗ NCT07116850 ↗ NCT00108368 ↗ NCT00249119 ↗ NCT00992407 ↗ NCT03568500 ↗ NCT03160521 ↗ NCT00654576 ↗ NCT00391222 ↗ NCT00790075 ↗ NCT00266552 ↗ NCT00000342 ↗ NCT00236548 ↗ NCT04071639 ↗ NCT00457106 ↗ NCT00249145 ↗ NCT01607762 ↗ NCT00249132 ↗ NCT00000339 ↗ NCT00166595 ↗ NCT00660595 ↗ NCT00694707 ↗ NCT00095134 ↗ NCT06482554 ↗ NCT00133822 ↗ NCT00169988 ↗ NCT00571688 ↗ NCT02926976 ↗ NCT01510015 ↗ NCT00140426 ↗ NCT01086748 ↗ NCT04446234 ↗ NCT00330551 ↗ NCT00053703 ↗ NCT01155921 ↗ NCT00848432 ↗ NCT00257075 ↗ NCT01171937 ↗ NCT00796302 ↗ NCT02658357 ↗ NCT07665073 ↗ NCT01639872 ↗ NCT02137616 ↗ NCT02307396 ↗ NCT00224315 ↗ NCT00817648 ↗ NCT05401019 ↗ NCT01931059 ↗ NCT06368726 ↗ NCT00827840 ↗ NCT02431702 ↗ NCT00629252 ↗ NCT02634463 ↗ NCT00269035 ↗ NCT04580134 ↗ NCT01677377 ↗ NCT00932529 ↗ NCT00352196 ↗ NCT02650102 ↗ NCT00203528 ↗ NCT03148509 ↗ NCT03019887 ↗ NCT00435370 ↗ NCT01977300 ↗ NCT05779241 ↗ NCT00012558 ↗ NCT00794625 ↗ NCT03978832 ↗ NCT00829894 ↗ NCT04587115 ↗ NCT00364429 ↗ NCT03510325 ↗ NCT00132314 ↗ NCT00893256 ↗ NCT02118688 ↗ NCT02573701 ↗ NCT00000317 ↗ NCT01788774 ↗ NCT00065273 ↗ NCT00236470 ↗ NCT00245206 ↗ NCT00006195 ↗ NCT01155934 ↗ NCT05542264 ↗ NCT01083381 ↗ NCT00284206 ↗ NCT00183625 ↗ NCT00698022 ↗ NCT00086112 ↗ NCT03837860 ↗ NCT00423878 ↗ NCT00176202 ↗ NCT06581302 ↗ NCT02593734 ↗ NCT00236457 ↗ NCT00179062 ↗ NCT00485498 ↗ NCT00622011 ↗ NCT04512066 ↗ NCT00711269 ↗ NCT00004393 ↗ NCT07541157 ↗ NCT04478838 ↗ NCT00806234 ↗ NCT00221403 ↗ NCT00236444 ↗ NCT00261508 ↗ NCT00716755 ↗ NCT00208143 ↗ NCT02086786 ↗ NCT00509067 ↗ NCT00480844 ↗ NCT03227562 ↗ NCT03075657 ↗ NCT02456454 ↗ NCT00563706 ↗ NCT07575516 ↗ NCT01623713 ↗ NCT06768944 ↗ NCT01157351 ↗ NCT00856583 ↗ NCT00157378 ↗ NCT03323437 ↗ NCT01670071 ↗ NCT00159770 ↗ NCT00289861 ↗ NCT00825045 ↗ NCT00563017 ↗ NCT00845026 ↗ NCT07152184 ↗ NCT00576732 ↗ NCT00493233 ↗ NCT00374764 ↗ NCT00526877 ↗ NCT00337662 ↗ NCT02192723 ↗ NCT00014001 ↗ NCT03055338 ↗ NCT07477301 ↗ NCT00645515 ↗ NCT00236379 ↗ NCT00178854 ↗ NCT03790085 ↗ NCT00567710 ↗ NCT00076115 ↗ NCT00015548 ↗ NCT02453893 ↗ NCT00272597 ↗ NCT00177567 ↗ NCT00508157 ↗ NCT00005014 ↗ NCT00645372 ↗ NCT00254930 ↗ NCT00722176 ↗ NCT01234454 ↗ NCT03883204 ↗ NCT07523256 ↗ NCT02019329 ↗ NCT00604279 ↗ NCT00768612 ↗ NCT00256997 ↗ NCT00621998 ↗ NCT00314613 ↗ NCT02758067 ↗ NCT00130923 ↗ NCT00946985 ↗ NCT07503002 ↗ NCT00174577 ↗ NCT01284959 ↗ NCT02002832 ↗ NCT00277654 ↗ NCT00044655 ↗ NCT07671040 ↗ NCT00272584 ↗ NCT07060872 ↗ NCT02661347 ↗ NCT00034775 ↗ NCT03730857 ↗ NCT00236353 ↗ NCT00203788 ↗ NCT00640562 ↗ NCT03090503 ↗ NCT01626872 ↗ NCT04529226 ↗ NCT00594269 ↗ NCT01057849 ↗ NCT00385801 ↗ NCT00000310 ↗ NCT00857818 ↗ NCT02051387 ↗ NCT05179525 ↗ NCT06200584 ↗ NCT01259973 ↗ NCT00034762 ↗ NCT00044681 ↗ NCT01896349 ↗ NCT06878833 ↗ NCT00208819 ↗ NCT03230864 ↗ NCT00000309 ↗ NCT02374567 ↗ NCT02469155 ↗ NCT00653406 ↗ NCT02717195 ↗ NCT02535156 ↗ NCT01175135 ↗ NCT00330863 ↗ NCT01786239 ↗ NCT00641745 ↗ NCT04624243 ↗ NCT00227123 ↗ NCT00049946 ↗ NCT00535132 ↗ NCT00366704 ↗ NCT00034580 ↗ NCT00205699 ↗ NCT00308360 ↗ NCT05890768 ↗ NCT00203775 ↗ NCT00206102 ↗ NCT00174590 ↗ NCT00314327 ↗ NCT02282085 ↗ NCT01499563 ↗ NCT01050582 ↗ NCT04105231 ↗ NCT02063945 ↗ NCT02021201 ↗ NCT01282632 ↗ NCT07524868 ↗ NCT01140620 ↗ NCT00254241 ↗ NCT01376076 ↗ NCT00034749 ↗ NCT00205738 ↗ NCT00534183 ↗ NCT00761670 ↗ NCT00000267 ↗ NCT00167154 ↗ NCT01888107 ↗ NCT00177164 ↗ NCT00934635 ↗
Known as	(Risperdal M-TAB) tablets of Janssen Pharmaceutica Products	“(Risperdal M-TAB) tablets of Janssen Pharmaceutica Products” NCT01155921 ↗
Known as	Antipsychotic	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01724372 ↗
Known as	Consta	“Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks” NCT00177164 ↗ 1 “Depot Risperidone Microsphere (Consta)” NCT00215579 ↗
Known as	EN3342	“EN3342 (risperidone) subcutaneous implant” NCT01774435 ↗
Known as	Flufenazine	“Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗
Known as	LYN-005	“Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone.” NCT05779241 ↗ 2 “LYN-005 (risperidone)” NCT06878833 ↗ NCT04567524 ↗
Known as	Oral Ris	“Risperidone, administered orally (Oral Ris)” NCT00333177 ↗
Known as	Oral Risperidone	“Drug: Oral Risperidone” NCT02431702 ↗
Known as	Perfenazine	“Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗
Known as	QUAR	“quarterly Risperidone (QUAR)” NCT06276361 ↗
Known as	R064766	“A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder” NCT01624675 ↗
Known as	RBP-7000	“RBP-7000, a recently marketed long-acting subcutaneous injectable risperidone formulation, were examined to determine if dose-response relationships existed for different items...” PMID 34551218 ↗ Sep 2021 5 “A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.” NCT02687984 ↗ NCT02203838 ↗ NCT02768649 ↗ NCT02765555 ↗ NCT01677377 ↗
Known as	RCN3028	“A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women” NCT02100540 ↗ 1 NCT06161792 ↗
Known as	RIS	“OBJECTIVES: I. Conduct a randomized, double blind, placebo controlled, parallel study of the atypical neuroleptic risperidone (RIS) in the treatment of children and adults with...” NCT00004393 ↗ 2 “Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)” NCT01742390 ↗ “4. 320 begin double-blind treatment with risperidone (RIS)” NCT00014001 ↗
Known as	RIS-LAI	“injectable atypical antipsychotic paliperidone palmitate (PP) versus risperidone long-acting injectable (RIS-LAI)” PMID 21092748 ↗ Nov 2010
Known as	RISP	“This study compared the efficacy in reducing aggressive behavior of risperidone (RISP), divalproex sodium (DVPX), and placebo (PBO) added to stimulant medication among...” PMID 32007604 ↗ Jan 2020
Known as	Risperdal	“The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test...” NCT00179244 ↗ 20 “This study was developed in order to assess the effects of risperidone (Risperdal) as compared with placebo on cognitive-motor performance (attention, memory, and hand...” NCT00399698 ↗ “An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or...” NCT00236353 ↗ “A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children” NCT00254930 ↗ “This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.” NCT00000374 ↗ “The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder” NCT00250367 ↗ “The changes in brain chemicals that occur when an SSRI type antidepressant is supplemented with risperidone (Risperdal®) will be studied.” NCT00178854 ↗ “Switched From RISPERDAL® Tablets (Risperidone) to an Equivalent Dose of a rapidly-dissolving Tablet Formulation of Risperdone” NCT00246272 ↗ “This study will compare the safety and effectiveness two medications, citalopram (Celexa®) and risperidone (Risperdal®).” NCT00073658 ↗ “Long actiing risperidone injection (Consta), oral risperidone (risperdal).” NCT00177164 ↗ “olanzapine (Zyprexa), risperidone (Risperdal) or quetiapine (Seroquel)” NCT00048802 ↗ “compared to the atypical antipsychotic, risperidone (Risperdal).” NCT00208143 ↗ “Risperdal (risperidone) versus Zyprexa (olanzapine)” NCT00179062 ↗ “risperidone( Risperdal), zotepine( Lodopine)” NCT00622011 ↗ “risperidone (Risperdal®)” NCT02237417 ↗ “risperidone (Risperdal)” NCT00167479 ↗ “risperidone (Risperdal)” NCT00181935 ↗ NCT04639960 ↗ NCT00056498 ↗ NCT00910780 ↗ NCT00626613 ↗
Known as	Risperdal (risperidone) Consta	“Risperdal (risperidone) Consta” NCT00571688 ↗
Known as	RISPERDAL CONSTA	“A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2...” NCT00297388 ↗ 12 “The purpose of this study is to examine the safety and effectiveness of the long acting injectable form of the atypical antipsychotic Risperidone (Risperdal CONSTA), along with...” NCT00094926 ↗ “The purpose of this trial is to evaluate the long-term effectiveness of Risperdal® Consta®, a long-acting injectable antipsychotic medication, versus Abilify®, an oral...” NCT00299702 ↗ “The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit...” NCT00148083 ↗ “An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or...” NCT00236353 ↗ “A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)” NCT00216528 ↗ “long-acting injectable risperidone (RISPERDAL® CONSTA™) compared with the previous treatment with oral olanzapine” NCT00216632 ↗ “The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta).” NCT00539071 ↗ “RISPERDAL CONSTA (risperidone long-acting injection) may provide substantial improvement” NCT00132678 ↗ “RISPERDAL CONSTA (Risperidone Long-Acting Intramuscular Injection)” NCT00589914 ↗ NCT00132678 ↗ NCT02411526 ↗ NCT00313391 ↗
Known as	Risperidone ISM	“The primary objective of this study was to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once-daily 4 mg...” NCT05179525 ↗
Known as	Risperidone LAI	“a long-acting injectable formulation of risperidone (risperidone LAI)” NCT00236587 ↗ 1 “Risperidone LAI 37.5 mg” NCT01888107 ↗
Known as	Risperidone Long-Acting Injection (RLAI)	“Risperidone Long-Acting Injection (RLAI) (Period 1)” NCT00378092 ↗
Known as	Risperidone Long-Acting Intramuscular Injection	“RISPERDAL CONSTA (Risperidone Long-Acting Intramuscular Injection)” NCT00589914 ↗
Known as	Risperidone microspheres	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00330863 ↗
Known as	Risperidone, H20010309	“Risperidone, H20010309” NCT04071639 ↗
Known as	Risperidone-SABER	“ZX003 (Risperidone-SABER®)” NCT02411526 ↗
Known as	RLAI	“Participants were randomly assigned at a 2:1 ratio to a recommendation of changing to LAI risperidone microspheres (RLAI) (n = 26) or continuing oral antipsychotic treatment (n...” PMID 22938760 ↗ Aug 2012 7 “Long-term treatment with risperidone long-acting injectable (RLAI), the first available long-acting atypical antipsychotic, versus oral atypical antipsychotics showed better...” PMID 22339430 ↗ Apr 2012 “This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.” PMID 24583566 ↗ Sep 2014 “Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis” NCT00369239 ↗ “Risperidone Long-Acting Injection (RLAI) (Period 1)” NCT00378092 ↗ “Risperidone, administered via injection (RLAI)” NCT00333177 ↗ “risperidone long-acting injectable (RLAI)” NCT01888107 ↗ “Risperidone Long-Acting Injectable (RLAI)” NCT00269919 ↗
Known as	RLAT	“This study assessed whether adjunctive maintenance treatment with risperidone long-acting therapy (RLAT), added to treatment-as-usual (TAU) medications for bipolar disorder,...” PMID 19922552 ↗ Dec 2009
Known as	RYKINDO	“RYKINDO® (Rykindo) is a novel, long-acting injectable risperidone formulation administered biweekly (Q2W) through intramuscular gluteal injection for the treatment of...” PMID 38244179 ↗ Jan 2024
Known as	TV-46000	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03503318 ↗ 1 NCT03893825 ↗
Known as	ZX003	“ZX003 (Risperidone-SABER®)” NCT02411526 ↗
Action	Inhibit	“risperidone's relatively potent dopamine D2 receptor blockade” PMID 26302441 ↗ Oct 2015
Modality	Other / unclassified	“an antipsychotic medication” NCT00266552 ↗
Route	Oral	“as an oral solution each day” NCT00034749 ↗